동물 광견병 백신 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Veterinary Rabies Vaccines Market was valued at USD 502.5 million in 2023 and is projected to grow at 4.2% CAGR from 2024 to 2032, attributed to the rising prevalence of rabies in animals and the growing awareness of its zoonotic implications.

The global surge in pet ownership has further propelled the market, as owners increasingly recognize the importance of vaccinating their pets against rabies. Urbanization and the growth of livestock farming in developing nations are also driving the demand for rabies vaccines, integrated into broader animal health management strategies. Additionally, government-backed initiatives, especially mass vaccination campaigns, are set to bolster the market's growth in the foreseeable future.

The rising incidence of rabies serves as a primary market driver. Data from the World Organization of Animal Health (WOAH) highlights the severity: rabies accounts for roughly 59,000 annual fatalities, with a staggering 99% stemming from dog bites. This viral menace predominantly targets mammals, including common domestic pets like dogs and cats, and boasts an almost 100% fatality rate post-symptom onset. Such dire statistics have galvanized global efforts to combat rabies, culminating in extensive vaccination drives.

The global veterinary rabies vaccines industry is classified based on animal type, application, end-use, route of administration and region.

The market categorizes based on animal type into companion animals, livestock, and wildlife. The companion segment, further divided into dogs, cats, and others, led the market with a valuation of USD 264.6 million in 2023. Heightened awareness among pet owners about rabies vaccination's significance, combined with a global uptick in pet ownership, has driven this demand. Given that dogs and cats are primary rabies reservoirs for humans, their vaccination becomes paramount for public health. Furthermore, many countries' regulations mandating pet rabies vaccinations underscore the companion segment's market dominance.

Application-wise, the market divides into pre-exposure and post-exposure prophylaxis. The post-exposure segment led with a commanding 69.7% share in 2023. Its dominance stems from its pivotal role in thwarting rabies onset after potential exposure. Veterinary PEP vaccines play a crucial role in protecting animals, especially pets and livestock, from rabies through contact with infected entities. The near-certain fatality of rabies post-symptom emergence amplifies the demand and significance of PEP in the market.

North America Veterinary Rabies Vaccines Industry was valued at USD 197.6 million. Projections indicate a growth at a CAGR of 3.8% from 2024 to 2032. The region is characterized by a strong veterinary healthcare infrastructure, an increase in awareness among pet owners, and strict government regulations that mandate rabies vaccinations for pets. Additionally, the market's dominance is further strengthened by the presence of major pharmaceutical companies and their active research and development efforts. The combination of a high prevalence of rabies in wildlife and strong public health initiatives highlights the demand for veterinary rabies vaccines in North America, reinforcing the region's position as a global leader.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of rabies
    • 3.2.1.2 Rising pet ownership globally
    • 3.2.1.3 Favorable government regulations and policies
    • 3.2.1.4 Increased awareness about rabies and its prevention
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of rabies vaccines
    • 3.2.2.2 Lack of awareness
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Companion animals
  • 5.2.1 Dogs
  • 5.2.2 Cats
  • 5.2.3 Other companion animals
• 5.3 Livestock animals
  • 5.3.1 Cattle
  • 5.3.2 Sheep and goats
  • 5.3.3 Other livestock animals
• 5.4 Wildlife

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pre exposure prophylaxis
• 6.3 Post exposure prophylaxis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals and clinics
• 8.3 Animal shelters and rescue organizations
• 8.4 Research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Biogenesis Bago S.A.
• 10.2 Bioveta, a.s.
• 10.3 Boehringer Ingelheim International GmbH
• 10.4 Ceva Sante Animale S.A.
• 10.5 Dyntec
• 10.6 Elanco Animal Health Incorporated
• 10.7 Indian Immunologicals Limited
• 10.8 Merck and Co., Inc.
• 10.9 Vaxxinova International B.V.
• 10.10 Virbac S.A.
• 10.11 Zoetis Inc.